Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant in Treatment Refractory Trigeminal Neuralgia
NCT03941834Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in trigeminal neuralgia (TN) comparing BHV3000 with Placebo (2 arms). Primary endpoint: Change From Baseline in the Average Daily Pain Score on Numeric Pain Rating Scale (NPRS) at 2 weeks. Started Jun 2019; status: terminated.
02
Drugs
rimegepant
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT03941834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941834.